Cargando…

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsigkas, Grigorios, Vakka, Angeliki, Apostolos, Anastasios, Bousoula, Eleni, Vythoulkas-Biotis, Nikolaos, Koufou, Eleni-Evangelia, Vasilagkos, Georgios, Tsiafoutis, Ioannis, Hamilos, Michalis, Aminian, Adel, Davlouros, Periklis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144375/
https://www.ncbi.nlm.nih.gov/pubmed/37103014
http://dx.doi.org/10.3390/jcdd10040135
_version_ 1785034085217861632
author Tsigkas, Grigorios
Vakka, Angeliki
Apostolos, Anastasios
Bousoula, Eleni
Vythoulkas-Biotis, Nikolaos
Koufou, Eleni-Evangelia
Vasilagkos, Georgios
Tsiafoutis, Ioannis
Hamilos, Michalis
Aminian, Adel
Davlouros, Periklis
author_facet Tsigkas, Grigorios
Vakka, Angeliki
Apostolos, Anastasios
Bousoula, Eleni
Vythoulkas-Biotis, Nikolaos
Koufou, Eleni-Evangelia
Vasilagkos, Georgios
Tsiafoutis, Ioannis
Hamilos, Michalis
Aminian, Adel
Davlouros, Periklis
author_sort Tsigkas, Grigorios
collection PubMed
description Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.
format Online
Article
Text
id pubmed-10144375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101443752023-04-29 Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review Tsigkas, Grigorios Vakka, Angeliki Apostolos, Anastasios Bousoula, Eleni Vythoulkas-Biotis, Nikolaos Koufou, Eleni-Evangelia Vasilagkos, Georgios Tsiafoutis, Ioannis Hamilos, Michalis Aminian, Adel Davlouros, Periklis J Cardiovasc Dev Dis Review Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population. MDPI 2023-03-23 /pmc/articles/PMC10144375/ /pubmed/37103014 http://dx.doi.org/10.3390/jcdd10040135 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tsigkas, Grigorios
Vakka, Angeliki
Apostolos, Anastasios
Bousoula, Eleni
Vythoulkas-Biotis, Nikolaos
Koufou, Eleni-Evangelia
Vasilagkos, Georgios
Tsiafoutis, Ioannis
Hamilos, Michalis
Aminian, Adel
Davlouros, Periklis
Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title_full Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title_fullStr Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title_full_unstemmed Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title_short Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
title_sort dual antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144375/
https://www.ncbi.nlm.nih.gov/pubmed/37103014
http://dx.doi.org/10.3390/jcdd10040135
work_keys_str_mv AT tsigkasgrigorios dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT vakkaangeliki dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT apostolosanastasios dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT bousoulaeleni dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT vythoulkasbiotisnikolaos dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT koufouelenievangelia dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT vasilagkosgeorgios dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT tsiafoutisioannis dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT hamilosmichalis dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT aminianadel dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview
AT davlourosperiklis dualantiplatelettherapyandcancerbalancingbetweenischemicandbleedingriskanarrativereview